A Long-term Follow-up Study in Participants Who Received CS-101

CorrectSequence Therapeutics

Status: Invitation-only

Conditions: Beta-Thalassemia

Treatments: Other: Safety and efficacy assessments

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06685536

CS-101-13

Details and patient eligibility

About

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.

Full description

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876). Subjects in the CS-101-06 study will be entered into long-term follow-up of this study up to 15 years post-infusion at the completion of the last (12-month) followup visit after treatment with CS-101 Injection.

Enrollment: 5 estimated patients

Sex: All

Ages: 6 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form
• Participants must have received CS-101 infusion in last study

Exclusion criteria

• There are no exclusion criteria